Shares of Mirati Therapeutics (MRTX) have risen by 630% since my September 2017 article stated that a double on early data for sitravatinib could be just the beginning. On the other hand, the stock has fallen by 17% since my June update piece detailed how the company "won" at ASCO without even presenting data for its KRAS G12C inhibitor MRTX849.
Today, I'm choosing to revisit this targeted oncology story now that management has confirmed initial data for MRTX849 should be coming in the fourth quarter (perhaps AACR-NCI-EORTC in late October).
Chart
Figure 1: